Monitoring Hemophilia A Therapy: HeliTrax®


Hemophilia A patients who use Helixate® FS, Antihemophilic Factor (Recombinant), and their treatment providers can track treatment progress in real time, with the HeliTrax® System, a state-of-the-art wireless Internet-based data management system. The system allows for a comprehensive view of a patient's progress, with young patients relaying information about hemophilia A symptoms (i.e., bleeding events) and their use of Helixate® FS to their hemophilia treatment center via the handheld device or web interface between office visits. The HeliTrax® System, used in conjunction with Helixate® FS treatment, is designed to improve patient-physician communications and hemophilia A treatment.

Physicians monitoring hemophilia A patients often rely on paper forms filled out by the patients or their caregivers, which do not always provide necessary clinical information, such as the appearance of hemophilia A symptoms, in a timely, clear and concise way. HeliTrax® not only tracks a patient's therapy as it happens — including medication usage and inventory — but allows the hemophilia treatment center to generate a one-page, easy-to-read, full-color clinical report of the patient's progress. These private, secure reports, which help reduce documentation and transcription errors, are compliant with both the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and the Health Insurance Portability and Accountability Act (HIPAA).

"I love it. As complicated as things are when you have a child with hemophilia, the HeliTrax® System just makes life 150 percent easier."
— Shirley Smith, Hariman, Tennessee

“HeliTrax allows us to receive real-time reporting of bleeds in our patients. Previously, we reviewed that history every 6 months at the comprehensive visit. This gives us the ability to intervene sooner when we determine a patient has developed a target joint.”
— Margy Sennett, RN, MS, University of Virginia Children’s Hospital

For Healthcare Professionals »

For Patients »

Important Safety Information

Helixate® FS, Antihemophilic Factor (Recombinant), is a recombinant factor VIII treatment indicated for the control and prevention of bleeding episodes and peri-operative management in adults and children (0-16 years) with hemophilia A. Helixate® FS is also indicated for routine prophylaxis to reduce the frequency of bleeding episodes and the risk of joint damage in children with hemophilia A with no preexisting joint damage.

The most serious adverse reactions are systemic hypersensitivity reactions and the development of high-titer inhibitors necessitating alternative treatments to antihemophilic factor. The most common adverse reactions observed in clinical trials were inhibitor formation in previously untreated or minimally treated patients, skin-associated hypersensitivity reactions, infusion site reactions, and central venous access device (CVAD) line-associated infections.

Helixate® FS is contraindicated in patients who have manifested life-threatening immediate hypersensitivity reactions, including anaphylaxis, to the product or its components, including mouse or hamster proteins.

Please see the full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.